AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19467054 — intervention group
Group type: COMPARATOR
Intervention: Calcium hydroxide [Ca(OH)(2)]
Number of subjects: 15
Study 19467054 — intervention group
Group type: COMPARATOR
Intervention: Both groups (EMDgel and Ca(OH)(2))
Number of subjects: 15
Study 16708123 — intervention group
Group type: EXPERIMENTAL
Intervention: Pycnogenol 150 mg or 300 mg daily for 8 weeks
Number of subjects: 86
Study 16708123 — intervention group
Group type: COMPARATOR
Intervention: Daflon 1,000 mg/day
Number of subjects: 86
Study 16279275 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete case analysis
Number of subjects: 71
Study 16279275 — intervention group
Group type: EXPERIMENTAL
Intervention: Imputation using baseline values or worst case value
Number of subjects: 71
Study 16279275 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated measures analysis
Number of subjects: 71
Study 16279275 — intervention group
Group type: EXPERIMENTAL
Intervention: Last observation carried forward
Number of subjects: 71
Study 16279275 — intervention group
Group type: EXPERIMENTAL
Intervention: Imputation with worst case value
Number of subjects: 71
Study 16279275 — intervention group
Group type: EXPERIMENTAL
Intervention: Imputation using regression predictions
Number of subjects: 71
Study 16279275 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitivity analysis
Number of subjects: 71
Study 11152792 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced MR angiography (MIP images)
Number of subjects: 50
Study 11152792 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced MR angiography (reformatted transverse source images)
Number of subjects: 50
Study 11152792 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced MR angiography
Number of subjects: 50
Study 11152792 — intervention group
Group type: COMPARATOR
Intervention: Conventional angiography
Number of subjects: 50
Study 11152792 — intervention group
Group type: EXPERIMENTAL
Intervention: MIP images
Number of subjects: 50
Study 11152792 — intervention group
Group type: EXPERIMENTAL
Intervention: Source images
Number of subjects: 50
Study 9266231 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfuzosin 2.5 mg t.i.d. for 4 weeks
Number of subjects: 94
Study 9266231 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 94
Study 9266231 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfuzosin (single-blind) during the 8-week extension period
Number of subjects: 94
Study 8336198 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg alendronate
Number of subjects: 59
Study 8336198 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg alendronate
Number of subjects: 59
Study 8336198 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg alendronate (2-hour infusion)
Number of subjects: 59
Study 8336198 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg alendronate (24-hour infusion)
Number of subjects: 59
Study 8336198 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg alendronate
Number of subjects: 59
Study 8336198 — intervention group
Group type: EXPERIMENTAL
Intervention: >= 5 mg alendronate
Number of subjects: 59
Study 8336198 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 59
Study 6355263 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefamandole
Number of subjects: 200
Study 6355263 — intervention group
Group type: COMPARATOR
Intervention: Nafcillin
Number of subjects: 200
Study 31614946 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent exercise program (9 months)
Number of subjects: 47
Study 31614946 — intervention group
Group type: EXPERIMENTAL
Intervention: Detraining (3 months)
Number of subjects: 47
Study 31614946 — intervention group
Group type: COMPARATOR
Intervention: Normal activities (Control Group)
Number of subjects: 47
Study 28881359 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat HPV-negative test in HPV-positive women with normal cytology
Number of subjects: 9279
Study 28881359 — intervention group
Group type: COMPARATOR
Intervention: HPV-negative women with normal cytology (double negatives)
Number of subjects: 9279
Study 25843603 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin-modified glass ionomer cement varnish
Number of subjects: 480
Study 25843603 — intervention group
Group type: COMPARATOR
Intervention: Control (no varnish)
Number of subjects: 480
Study 24729994 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality simulator training (16 hours)
Number of subjects: 18
Study 24729994 — intervention group
Group type: COMPARATOR
Intervention: No training (Control)
Number of subjects: 18
Study 22074059 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabergoline (0.25 mg twice weekly for 4 weeks followed by 0.5 mg twice weekly for the next 12 weeks)
Number of subjects: 40
Study 22074059 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 19649245 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S/AS01B
Number of subjects: 255
Study 19649245 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S/AS02A
Number of subjects: 255
Study 19649245 — intervention group
Group type: COMPARATOR
Intervention: Rabies vaccine (Rabipur; Chiron Behring GmbH)
Number of subjects: 255
Study 18091519 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus 1.5 mg/day
Number of subjects: 634
Study 18091519 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus 3 mg/day
Number of subjects: 634
Study 18091519 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (both dosages)
Number of subjects: 634
Study 18091519 — intervention group
Group type: COMPARATOR
Intervention: AZA
Number of subjects: 634
Study 16857508 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrophobic acrylic IOL (AcrySof MA60, Alcon)
Number of subjects: 35
Study 16857508 — intervention group
Group type: COMPARATOR
Intervention: Plate-haptic silicone IOL (C11UB, Chiron)
Number of subjects: 35
Study 12764713 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzodiazepine Dependence Self-Report Questionnaire (Bendep-SRQ)
Number of subjects: 180
Study 10100071 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha 2 exon 21-22 marker
Number of subjects: 533
Study 10100071 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha 2 haplotype
Number of subjects: 533
Study 10100071 — intervention group
Group type: EXPERIMENTAL
Intervention: beta 1 Msp I marker
Number of subjects: 533
Study 10100071 — intervention group
Group type: EXPERIMENTAL
Intervention: beta 1 haplotype
Number of subjects: 533
Study 10100071 — intervention group
Group type: EXPERIMENTAL
Intervention: beta 1 markers
Number of subjects: 533
Study 10100071 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha 2 exon 21-22 genotype
Number of subjects: 533
Study 8738670 — intervention group
Group type: EXPERIMENTAL
Intervention: Sandimmun Optoral
Number of subjects: 28
Study 8738670 — intervention group
Group type: COMPARATOR
Intervention: Sandimmun
Number of subjects: 28
Study 1930075 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine ingestion (3.3 mg/kg body weight)
Number of subjects: 11
Study 1930075 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 6349363 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrofurantoin suppressive therapy
Number of subjects: 200
Study 6349363 — intervention group
Group type: COMPARATOR
Intervention: Close surveillance
Number of subjects: 200
Study 31074779 — intervention group
Group type: EXPERIMENTAL
Intervention: Effect allele of rs1051730
Number of subjects: 393122
Study 29044133 — intervention group
Group type: EXPERIMENTAL
Intervention: High water availability (W+)
Number of subjects: 737
Study 29044133 — intervention group
Group type: COMPARATOR
Intervention: Low water availability (W-)
Number of subjects: 737
Study 26374140 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily supplementation with antioxidant nutrients (vitamin C 120 mg, β-carotene 6 mg, vitamin E 30 mg, selenium 100 µg, zinc 20 mg)
Number of subjects: 3966
Study 23256821 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid ingestion (FL) - 5 ml kg(‐1) before and 2 ml kg(‐1) every 15 min
Number of subjects: 8
Study 23256821 — intervention group
Group type: COMPARATOR
Intervention: No fluid ingestion (NF)
Number of subjects: 8
Study 23256821 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid ingestion (FL)
Number of subjects: 8
Study 21739689 — intervention group
Group type: EXPERIMENTAL
Intervention: Penetrating needling on head points (group A)
Number of subjects: 60
Study 21739689 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture of syndrome division (group B)
Number of subjects: 60
Study 19306364 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadobenate dimeglumine (0.1 mmol/kg)
Number of subjects: 46
Study 19306364 — intervention group
Group type: COMPARATOR
Intervention: Gadopentetate dimeglumine (0.1 mmol/kg)
Number of subjects: 46
Study 16858271 — intervention group
Group type: EXPERIMENTAL
Intervention: CMV prophylaxis
Number of subjects: 0
Study 12742010 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (500mg/day for 3 days)
Number of subjects: 8
Study 12742010 — intervention group
Group type: COMPARATOR
Intervention: Baseline measurements of CSA disposition kinetics (before azithromycin treatment)
Number of subjects: 8
Study 10701036 — intervention group
Group type: EXPERIMENTAL
Intervention: Nizatidine 300 mg
Number of subjects: 20
Study 10701036 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 9377958 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant postoperative external-beam radiation (EBR) of the bronchial stump and mediastinum (50 to 56 Gy, 8 or 23 MV photons, 2 Gy/d, 5 d/wk)
Number of subjects: 155
Study 9377958 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant postoperative external-beam radiation (EBR)
Number of subjects: 155
Study 9377958 — intervention group
Group type: COMPARATOR
Intervention: Control group (no further treatment)
Number of subjects: 155
Study 1492845 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimetindene maleate (DMM)
Number of subjects: 24
Study 1492845 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 24
Study 1492845 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 3903788 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 20 mg penbutolol plus 3 mg piretanide
Number of subjects: 51
Study 3903788 — intervention group
Group type: COMPARATOR
Intervention: 40 mg penbutolol alone
Number of subjects: 51
Study 30922609 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-session modified mindfulness-based cognitive therapy over 10 weeks
Number of subjects: 36
Study 30922609 — intervention group
Group type: COMPARATOR
Intervention: Usual family care and brief education on dementia care
Number of subjects: 36
Study 28265119 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 41
Study 28265119 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 27031740 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe normobaric hypoxia (SH; FiO2 = 13.3%; 3600 m)
Number of subjects: 13
Study 27031740 — intervention group
Group type: COMPARATOR
Intervention: Moderate normobaric hypoxia (MH; FiO2 = 16.8%; corresponding to 1800 m)
Number of subjects: 13
Study 25211921 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytodrug prolit super septo 2 capsules 2 times a day for 4 weeks
Number of subjects: 66
Study 25211921 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy only
Number of subjects: 66
Study 21393260 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded running programme with additional shockwave therapy (ESWT)
Number of subjects: 42
Study 21393260 — intervention group
Group type: COMPARATOR
Intervention: Graded running programme
Number of subjects: 42
Study 20538001 — intervention group
Group type: EXPERIMENTAL
Intervention: DFMO/sulindac
Number of subjects: 267
Study 20538001 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 267
Study 17851941 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar radiofrequency-induced thermotherapy (RFITT)
Number of subjects: 137
Study 17851941 — intervention group
Group type: COMPARATOR
Intervention: Standard blunt dissection tonsillectomy (TE)
Number of subjects: 137
Study 15681169 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ascorbic acid (AA) administration up to four times within 12 hours based on initial AA concentration (4x500 mg AA for <34.1 micromol/l; 2x500 mg AA for < or =56.8 micromol/l; 1x500 mg AA for < or =68.2 micromol/l)
Number of subjects: 57
Study 15681169 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 57
Study 11413075 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg per day for 4 weeks
Number of subjects: 15
Study 9916387 — intervention group
Group type: EXPERIMENTAL
Intervention: Emtrexate
Number of subjects: 10
Study 9916387 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate Remedica
Number of subjects: 10
Study 9916387 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate Lederle
Number of subjects: 10
Study 8063993 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Family Treatment (EFT)
Number of subjects: 147
Study 8063993 — intervention group
Group type: COMPARATOR
Intervention: Standard Family Treatment (SFT)
Number of subjects: 147
Study 3142454 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (12 young men) using a device supplying 12.8% O2 for 7.5-8 hours daily for 10 days.
Number of subjects: 22
Study 3142454 — intervention group
Group type: COMPARATOR
Intervention: Control group (10 young men) using a placebo device breathing normoxic air.
Number of subjects: 22
Study 3142454 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups exposed to 4500 m altitude after treatment.
Number of subjects: 22
Study 29872148 — intervention group
Group type: EXPERIMENTAL
Intervention: TEFOX regimen (docetaxel 50 mg/m2, oxaliplatin 85 mg/m2, 5FU 2400 mg/m2) administered every 14 days
Number of subjects: 65
Study 28131948 — intervention group
Group type: EXPERIMENTAL
Intervention: internet‐based cognitive behavioural therapy (ICBT)
Number of subjects: 946
Study 28131948 — intervention group
Group type: EXPERIMENTAL
Intervention: usual care (CBT or supportive counselling)
Number of subjects: 946
Study 28131948 — intervention group
Group type: EXPERIMENTAL
Intervention: exercise
Number of subjects: 946
Study 28131948 — intervention group
Group type: EXPERIMENTAL
Intervention: high availability of relationships
Number of subjects: 946
Study 28131948 — intervention group
Group type: COMPARATOR
Intervention: low availability of relationships
Number of subjects: 946
Study 25939030 — intervention group
Group type: EXPERIMENTAL
Intervention: Expressive Writing (EW)
Number of subjects: 146
Study 25939030 — intervention group
Group type: COMPARATOR
Intervention: Nonemotional Writing Instructions (Control)
Number of subjects: 146
Study 23293111 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential docetaxel (A (75 mg/m(2)) × 3 → docetaxel (T (100 mg/m(2)) × 3 → CMF)
Number of subjects: 2887
Study 23293111 — intervention group
Group type: COMPARATOR
Intervention: Sequential control (doxorubicin (A) (75 mg/m(2)) × 4 → CMF)
Number of subjects: 2887
Study 20826055 — intervention group
Group type: EXPERIMENTAL
Intervention: Advisor‐Teller Money Manager (ATM) treatment
Number of subjects: 90
Study 20826055 — intervention group
Group type: COMPARATOR
Intervention: Minimal‐attention control condition
Number of subjects: 90
Study 18056743 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ibuprofen
Number of subjects: 282
Study 18056743 — intervention group
Group type: COMPARATOR
Intervention: Oral ibuprofen
Number of subjects: 282
Study 16601430 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg PPS 3 times per day (300 mg/day)
Number of subjects: 168
Study 16601430 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg PPS 3 times per day (600 mg/day)
Number of subjects: 168
Study 16601430 — intervention group
Group type: COMPARATOR
Intervention: Placebo 3 times per day
Number of subjects: 168
Study 12830443 — intervention group
Group type: EXPERIMENTAL
Intervention: Short daily HD
Number of subjects: 45
Study 12830443 — intervention group
Group type: EXPERIMENTAL
Intervention: Long nocturnal HD
Number of subjects: 45
Study 12830443 — intervention group
Group type: COMPARATOR
Intervention: Conventional HD
Number of subjects: 45
Study 10877245 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% (w/w) glycolic acid scalp lotion
Number of subjects: 20
Study 10877245 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% (w/w) betamethasone scalp application
Number of subjects: 20
Study 10877245 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 10% glycolic acid lotion and 0.1% betamethasone
Number of subjects: 20
Study 8704119 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (30% C20:5 omega‐3 and 20% C22:6 omega‐3) at 6 g/day for 3 months
Number of subjects: 25
Study 8704119 — intervention group
Group type: COMPARATOR
Intervention: Coconut oil (63% C8:0 and 36% C10:0) at 6 g/day for 3 months (Control)
Number of subjects: 25
Study 1948127 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon
Number of subjects: 505
Study 1948127 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon/dexamethasone
Number of subjects: 505
Study 1948127 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 505
Study 6832206 — intervention group
Group type: EXPERIMENTAL
Intervention: Plain uncoated tablet (400 mg)
Number of subjects: 12
Study 6832206 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release tablet formulation 1 (400 mg)
Number of subjects: 12
Study 6832206 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release tablet formulation 2 (400 mg)
Number of subjects: 12
Study 6832206 — intervention group
Group type: COMPARATOR
Intervention: Intravenous aminophylline
Number of subjects: 12
Study 31207146 — intervention group
Group type: EXPERIMENTAL
Intervention: LUS (lung ultrasound)
Number of subjects: 442
Study 31207146 — intervention group
Group type: COMPARATOR
Intervention: Conventional management
Number of subjects: 442
Study 27802155 — intervention group
Group type: EXPERIMENTAL
Intervention: Vedolizumab (VDZ) therapy
Number of subjects: 41
Study 27958325 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA (100 U)
Number of subjects: 62
Study 27958325 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 62
Study 27958325 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA (100 U) in dysfunctional voiding patients
Number of subjects: 62
Study 27958325 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline) in dysfunctional voiding patients
Number of subjects: 62
Study 24857821 — intervention group
Group type: EXPERIMENTAL
Intervention: sibutramine
Number of subjects: 104
Study 24857821 — intervention group
Group type: EXPERIMENTAL
Intervention: shCBT + sibutramine
Number of subjects: 104
Study 24857821 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 104
Study 24857821 — intervention group
Group type: COMPARATOR
Intervention: shCBT + placebo
Number of subjects: 104
Study 23400973 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA cream
Number of subjects: 120
Study 23400973 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin (Myolaxin ointment)
Number of subjects: 120
Study 23400973 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA + capsaicin
Number of subjects: 120
Study 23400973 — intervention group
Group type: COMPARATOR
Intervention: Control (plain lubricant cream)
Number of subjects: 120
Study 20153216 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous LMWH 40 mg once per day
Number of subjects: 60
Study 20153216 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous LMWH 40 mg twice per day
Number of subjects: 60
Study 20153216 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 60
Study 18076018 — intervention group
Group type: EXPERIMENTAL
Intervention: Nissen fundoplication
Number of subjects: 127
Study 18076018 — intervention group
Group type: COMPARATOR
Intervention: Toupet fundoplication
Number of subjects: 127
Study 15717259 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunoadjuvant prednisolone therapy
Number of subjects: 0
Study 15717259 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12678152 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac tromethamine
Number of subjects: 120
Study 12678152 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone acetate
Number of subjects: 120
Study 12678152 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone acetate and fluorometholone acetate
Number of subjects: 120
Study 10673992 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation training with guided imagery and L-arginine
Number of subjects: 96
Study 10673992 — intervention group
Group type: COMPARATOR
Intervention: Placebo (dietary supplementation)
Number of subjects: 96
Study 8694083 — intervention group
Group type: EXPERIMENTAL
Intervention: Excimer laser phototherapeutic keratectomy
Number of subjects: 211
Study 1922173 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin (BTX) injection
Number of subjects: 42
Study 1922173 — intervention group
Group type: COMPARATOR
Intervention: Placebo injection
Number of subjects: 42
Study 6354122 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital-based program to improve pneumococcal immunization; Duration: Two successive winters.
Number of subjects: 1062
Study 6354122 — intervention group
Group type: EXPERIMENTAL
Intervention: Documentation of prior hospitalization within five years among adults with pneumococcal bacteremia; Population size: 61 adults.
Number of subjects: 1062
Study 6140351 — intervention group
Group type: EXPERIMENTAL
Intervention: General Health Questionnaire (GHQ) results made available to physicians (experimental group)
Number of subjects: 1452
Study 6140351 — intervention group
Group type: COMPARATOR
Intervention: No GHQ results made available to physicians (control group)
Number of subjects: 1452
Study 6140351 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with a prior diagnosis of a mental disorder
Number of subjects: 1452
Study 29981778 — intervention group
Group type: EXPERIMENTAL
Intervention: Test toothpaste containing 0.454% stannous fluoride
Number of subjects: 0
Study 29981778 — intervention group
Group type: COMPARATOR
Intervention: Control fluoride toothpaste containing 0.76% sodium monofluorophosphate
Number of subjects: 0
Study 29981778 — intervention group
Group type: COMPARATOR
Intervention: Mineral water
Number of subjects: 0